TABLE 9. P2Y₁₁ receptor (previously known as P2Y).

2.1:NUCT:5:P2Y₁₁

	TM	aa	AC	Chr. Map	References
Human	7	374	NM _002566*	19p13.2	Communi et al. (1997)

Functional assays

cAMP measurement in CHO-K1 cells stably expressing the P2Y11 receptor; IP3 measurement in 1321N1 astrocytoma cells stably expressing the P2Y11 receptor (Communi et al., 1997)

Ligand	Action	Selectivity	Endogenous	References
ATP	Agonist	No	Yes	Communi et al. (1999b)
ADP	Agonist	No	Yes	Communi et al. (1999b)
ATPγS	Agonist	No	No	Communi et al. (1999b)
BzATP	Agonist	No	No	Communi et al. (1999b)
dATP	Agonist	No	No	Communi et al. (1999b)
ADPβS	Agonist	No	No	Communi et al. (1999b)
2-MeSATP	Agonist	No	No	Communi et al. (1999b)
AR-C67085	Agonist	No	No	Communi et al. (1999b)
ADPγS	Partial agonist	No	No	Communi et al. (1999b)
AMPαS	Partial agonist	No	No	Communi et al. (1999b)
A3P5PS	Partial agonist	No	No	Communi et al. (1999b)
Suramin	Antagonist	No	No	Communi et al. (1999b)
Reactive blue 2	Antagonist	No	No	Communi et al. (1999b)
UTP	Agonist	No	Yes	White et al. (2003)

Agonist potencies**	cAMP: ATPγS (EC50 3.4 ± 0.3 μM) > BzATP (EC50 7.2 ± 0.5 μM) > dATP (EC50 8.9 ± 0.6 μM) > ATP (EC50 17.4 ± 6.1 μM) > ADPβS (EC50 29.7 ± 2.7 μM) > 2-MeSATP (EC50 50 ± 4 μM) (Communi et al., 1999b); IP3: BzATP (EC50 10.5 ± 0.3 μM) > ATPγS (EC50 13.5 ± 2.7 μM) > dATP (EC50 16.3 ± 0.7 μM) > ATP (EC50 65 ± 12 μM) > ADPβS (EC50 174 ± 28 μM) > 2-MeSATP (EC50 210 ± 6 μM) (Communi et al., 1999b)
Antagonist potencies	PI hydrolysis: suramin (IC50 1 μM), reactive blue 2 (IC50 9 μM); cAMP: suramin (IC50 16 μM) (Communi et al., 1999b)
Radioligand assays	None
Radioligands	None
Transduction mechanism	Gq/G11 and Gs (see “Comments”); PI hydrolysis (PLCβ activation) and elevated [Ca2+]i in expression systems; adenylate cyclase stimulation and elevated cAMP levels (Qi et al., 2001a)
Distribution	Brain, spleen, lymphocytes, intestine; all other tissues expressed more moderate levels of P2Y11 mRNA, with lowest levels detected in liver, cartilage, and bone (Moore et al., 2001)
Tissue function	Role in maturation, migration of dendritic cells (Wilkin et al., 2001; Schnurr et al., 2003), and in granulocytic differentiation (Communi et al., 2000); secretory role in pancreatic duct epithelial cells (Nguyen et al., 2001)
Phenotypes	None
Comments	In P2Y11 gene, an intron was found (Communi et al., 1997)*; P2Y11 couples to Gq and Gs, and the pharmacological profile of the GPCR is slightly different for each transduction pathway (PLCβ/IP3 and adenylate cyclase/cAMP) (Communi et al., 1999b; Qi et al., 2001a); the receptor does not activate PLA2 or PLD (Communi et al., 1999b); the P2Y12 antagonist ARC67085MX is an agonist here; a chimeric mRNA due to intergenic splicing between the P2Y11 and Ssf1 genes has been found in many mammalian cells— the function of this fusion protein is unknown (Communi et al., 2001); a canine (Qi et al., 2001a; Zambon et al., 2001) but no mouse and rat orthologs have been cloned; agonist potencies are species-dependent (Qi et al., 2001a; Zambon et al., 2001)**

aa, amino acids; AC, accession; chr., chromosome.